BNP/PUT/ELI LILLY & CO/300/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 01:20:41 27/06/2024 am IST | ||
| 0.007 EUR | -22.22% |
|
| 1 month | -50.00% | ||
| 3 months | -74.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 0.007 | -22.22% |
| 25/24/25 | 0.009 | +12.50% |
| 24/24/24 | 0.008 | -20.00% |
| 21/24/21 | 0.01 | +11.11% |
| 20/24/20 | 0.009 | +800.00% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC0LUV |
| ISIN | DE000PC0LUV9 |
| Date issued | 31/03/2023 |
| Strike | 300 $ |
| Maturity | 20/12/2024 (177 Days) |
| Parity | 10 : 1 |
| Emission price | 2.49 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.73 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Warrants
- Warrant
